Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 7/2012

01-07-2012 | Original Article

A significant association exists between receptor tyrosine kinase-like orphan receptor 2 gene variants and the OPG/RANKL ratio in human plasma

Authors: S. Ermakov, S. Trofimov, I. Malkin, G. Livshits

Published in: Osteoporosis International | Issue 7/2012

Login to get access

Abstract

Summary

There is a paucity of studies investigating association between ROR2 gene variants and osteoporosis and osteoarthritis-related phenotypes. The published literature suggests that osteoprotegerin (OPG) and receptor activator of nuclear factor-kB ligand (RANKL) are essential for bone metabolism and correlate with osteoarthritis manifestation and progression. The present study provides evidence of the significant association between ROR2 variants and the OPG/RANKL ratio in human plasma. The present results also suggest significant association between ROR2 polymorphisms and severity of radiographic hand osteoarthritis.

Introduction

Despite the importance of the ROR-2 in skeletal physiology, there is a paucity of studies investigating the potential association of ROR2 gene variants with phenotypes relevant to osteoporosis and osteoarthritis. On the other hand, there is a considerable body of literature suggesting that OPG and RANKL and their ratio (OPG/RANKL) are essential for regulating bone resorption. This is also correlated with osteoarthritis manifestation and progression. The present study therefore examines whether ROR2 polymorphisms may be associated with the OPG/RANKL ratio and hand osteoarthritis (HOA).

Methods

The study was conducted in a family-based sample of 1,515 Caucasian individuals, assessed for radiographic hand osteoarthritis, using the Kellgren/Lawrence score. Of these, 865 individuals were genotyped for 19 SNPs, relatively equally covering the ROR2 locus, and their plasma levels of OPG and RANKL were assayed. The association between the selected SNPs and OPG, along with the OPG/RANKL ratio and HOA, was explored using the pedigree disequilibrium test.

Results

Of the total of 57 tests, 16 nominally significant results (p < 0.05) were obtained, which is considerably more than the three normally expected for type I error. The significant association signals for all three phenotypes were mapped to the intron 1 region. The most significant results were detected between OPG/RANKL and rs7048756 (p < 0.0005) and between adjacent rs4744107 and Kellgren/Lawrence score (p = 0.006).

Conclusions

The present study provides evidence of the significant association between ROR2 variants and the OPG/RANKL ratio in human plasma and also suggests ROR2 association with HOA.
Literature
1.
Katoh M, Katoh M (2005) Comparative genomics on ROR1 and ROR2 orthologs. Oncol Rep 14(5):1381–1384PubMed
2.
Minami Y, Oishi I, Endo M, Nishita M (2010) Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases. Dev Dyn 239(1):1–15PubMed
3.
Afzal AR, Jeffery S (2003) One gene, two phenotypes: ROR2 mutations in autosomal recessive Robinow syndrome and autosomal dominant brachydactyly type B. Hum Mutat 22(1):1–11PubMedCrossRef
4.
5.
Schwabe GC, Tinschert S, Buschow C, Meinecke P, Wolff G, Gillessen-Kaesbach G, Oldridge M, Wilkie AO, Kömec R, Mundlos S (2000) Distinct mutations in the receptor tyrosine kinase gene ROR2 cause brachydactyly type B. Am J Hum Genet 67(4):822–831PubMedCrossRef
6.
DeChiara TM, Kimble RB, Poueymirou WT, Rojas J, Masiakowski P, Valenzuela DM, Yancopoulos GD (2000) Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development. Nat Genet 24(3):271–274PubMedCrossRef
7.
Billiard J, Way DS, Seestaller-Wehr LM, Moran RA, Mangine A, Bodine PV (2005) The orphan receptor tyrosine kinase Ror2 modulates canonical Wnt signaling in osteoblastic cells. Mol Endocrinol 19(1):90–101PubMedCrossRef
8.
Liu Y, Bhat RA, Seestaller-Wehr LM, Fukayama S, Mangine A, Moran RA, Komm BS, Bodine PV, Billiard J (2007) The orphan receptor tyrosine kinase Ror2 promotes osteoblast differentiation and enhances ex vivo bone formation. Mol Endocrinol 21(2):376–387PubMedCrossRef
9.
Green JL, Kuntz SG, Sternberg PW (2008) Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol 18(11):536–544PubMedCrossRef
10.
Nishita M, Enomoto M, Yamagata K, Minami Y (2010) Cell/tissue-tropic functions of Wnt5a signaling in normal and cancer cells. Trends Cell Biol 20(6):346–354PubMedCrossRef
11.
Enomoto M, Hayakawa S, Itsukushima S, Ren DY, Matsuo M, Tamada K, Oneyama C, Okada M, Takumi T, Nishita M, Minami Y (2009) Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 28(36):3197–3208PubMedCrossRef
12.
13.
Takaishi H, Kimura T, Dalal S, Okada Y, D’Armiento J (2008) Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Pharm Biotechnol 9(1):47–54PubMedCrossRef
14.
Fanjul-Fernández M, Folgueras AR, Cabrera S, López-Otín C (2010) Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta 1803(1):3–19PubMedCrossRef
15.
Li C, Chen H, Hu L, Xing Y, Sasaki T, Villosis MF, Li J, Nishita M, Minami Y, Minoo P (2008) Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2. BMC Mol Biol 9:11PubMedCrossRef
16.
Mikels AJ, Nusse R (2006) Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 4(4):e115PubMedCrossRef
17.
Mikels A, Minami Y, Nusse R (2009) Ror2 receptor requires tyrosine kinase activity to mediate Wnt5A signaling. J Biol Chem 284(44):30167–30176PubMedCrossRef
18.
Ermakov S, Malkin I, Keter M, Kobyliansky E, Livshits G (2007) Family-based association study of ROR2 polymorphisms with an array of radiographic hand bone strength phenotypes. Osteoporos Int 18(12):1683–1692PubMedCrossRef
19.
20.
Trouvin AP, Goëb V (2010) Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging 5:345–354PubMed
21.
Oh KW, Rhee EJ, Lee WY, Kim SW, Baek KH, Kang MI, Yun EJ, Park CY, Ihm SH, Choi MG, Yoo HJ, Park SW (2005) Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol (Oxf) 62(1):92–98CrossRef
22.
Wagner D, Fahrleitner-Pammer A (2010) Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help? Wien Med Wochenschr 160(17–18):452–457PubMedCrossRef
23.
Jabbar S, Drury J, Fordham JN, Datta HK, Francis RM, Tuck SP (2011) Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. J Clin Pathol 64(4):354–357PubMedCrossRef
24.
Jørgensen L, Hansen JB, Brox J, Mathiesen E, Vik A, Jacobsen BK (2011) Serum osteoprotegerin levels are related to height loss: The Tromsø Study. Eur J Epidemiol 26(4):305–312PubMedCrossRef
25.
Tat SK, Pelletier JP, Velasco CR, Padrines M, Martel-Pelletier J (2009) New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? Keio J Med 58(1):29–40PubMedCrossRef
26.
Moreno-Rubio J, Herrero-Beaumont G, Tardio L, Alvarez-Soria MA, Largo R (2010) Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. Arthritis Rheum 62(2):478–488PubMedCrossRef
27.
Livshits G, Karasik D, Kobyliansky E (2002) Complex segregation analysis of the radiographic phalanges bone mineral density and their age-related changes. J Bone Miner Res 17(1):152–161PubMedCrossRef
28.
Kalichman L, Malkin I, Livshits G, Kobyliansky E (2006) Age at menarche in a Chuvashian rural population. Ann Hum Biol 33(3):390–397PubMedCrossRef
29.
Kellgren J, Lawrence J (1963) Atlas of standard radiographs: the epidemiology of chronic rheumatism volume II. Blackwell, Oxford
30.
Kalichman L, Kobyliansky E, Livshits G (2006) Characteristics of joint degeneration in hand osteoarthritis. Joint Bone Spine 73(1):72–76PubMedCrossRef
31.
Trofimov S, Pantsulaia I, Kobyliansky E, Livshits G (2004) Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population. Eur J Endocrinol 150(3):305–311PubMedCrossRef
32.
International HapMap Consortium (2003) The international HapMap project. Nature 426(6968):789–796CrossRef
33.
Rhead B, Karolchik D, Kuhn RM, Hinrichs AS, Zweig AS, Fujita PA, Diekhans M, Smith KE, Rosenbloom KR, Raney BJ, Pohl A, Pheasant M, Meyer LR, Learned K, Hsu F, Hillman-Jackson J, Harte RA, Giardine B, Dreszer TR, Clawson H, Barber GP, Haussler D, Kent WJ (2010) The UCSC genome browser database: update 2010. Nucleic Acids Res 38(Database issue):D613–D619PubMedCrossRef
34.
Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263–265PubMedCrossRef
35.
Malkin I, Ginsburg E (2009) Program package for Mendelian analysis of pedigree data (MAN, Version 9). Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University; Technical Report
36.
Falconer DS, Mackay TFC (1996) Introduction to quantitative genetics, 4th edn. Longman, London
37.
Livshits G, Gerber LM (2001) Familial factors of blood pressure and adiposity covariation. Hypertension 37(3):928–935PubMed
38.
Korostishevsky M, Cohen Z, Malkin I, Ermakov S, Yarenchuk O, Livshits G (2010) Morphological and biochemical features of obesity are associated with mineralization genes’ polymorphisms. Int J Obes (Lond) 34(8):1308–1318CrossRef
39.
Suk EK, Malkin I, Dahm S, Kalichman L, Ruf N, Kobyliansky E, Toliat M, Rutsch F, Nürnberg P, Livshits G (2005) Association of ENPP1 gene polymorphisms with hand osteoarthritis in a Chuvasha population. Arthritis Res Ther 7(5):R1082–R1090PubMedCrossRef
40.
Benjamini Y, Yekutieli D (2001) The control of the false discovery rate in multiple testing under dependency. Ann Stat 29(4):1165–1188CrossRef
41.
Rogers A, Eastell R (2005) Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90(11):6323–6331PubMedCrossRef
42.
Hein GE, Meister M, Oelzner P, Franke S (2008) sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis. Rheumatol Int 28(8):765–769PubMedCrossRef
43.
Kearns AE, Khosla S, Kostenuik PJ (2008) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29(2):155–192PubMedCrossRef
44.
Livshits G, Pantsulaia I, Trofimov S, Kobyliansky E (2004) Genetic influences on the circulating cytokines involved in osteoclastogenesis. J Med Genet 41(6):e76PubMedCrossRef
45.
Livshits G (2005) Genetic epidemiology of skeletal system aging in apparently healthy human population. Mech Ageing Dev 126(2):269–279PubMedCrossRef
46.
Kawaguchi H (2009) Regulation of osteoarthritis development by Wnt-beta-catenin signaling through the endochondral ossification process. J Bone Miner Res 24(1):8–11PubMedCrossRef
47.
Blom AB, van Lent PL, van der Kraan PM, van den Berg WB (2010) To seek shelter from the WNT in osteoarthritis? WNT-signaling as a target for osteoarthritis therapy. Curr Drug Targets 11(5):620–629PubMedCrossRef
48.
Tamura M, Nemoto E, Sato MM, Nakashima A, Shimauchi H (2010) Role of the Wnt signaling pathway in bone and tooth. Front Biosci (Elite Ed) 2:1405–1413CrossRef
49.
Kubota T, Michigami T, Ozono K (2009) Wnt signaling in bone metabolism. J Bone Miner Metab 27(3):265–271PubMedCrossRef
50.
51.
Walsh NC, Gravallese EM (2010) Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 233(1):301–312PubMedCrossRef
52.
Sammar M, Sieber C, Knaus P (2009) Biochemical and functional characterization of the Ror2/BRIb receptor complex. Biochem Biophys Res Commun 381(1):1–6PubMedCrossRef
Metadata
Title
A significant association exists between receptor tyrosine kinase-like orphan receptor 2 gene variants and the OPG/RANKL ratio in human plasma
Authors
S. Ermakov
S. Trofimov
I. Malkin
G. Livshits
Publication date
01-07-2012
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 7/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-011-1820-x

Other articles of this Issue 7/2012

Osteoporosis International 7/2012 Go to the issue

Original Article

Anatomical distribution of vertebral fractures: comparison of pediatric and adult spines

Letter

Comment on: cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis

Original Article

Relationship between calcaneal quantitative ultrasound and hip dual energy X-ray absorptiometry in young healthy men

Original Article

Quality of life and health status with zoledronic acid and generic alendronate—a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass

Original Article

Mortality after vertebral fracture in Korea

Review

Frailty and sarcopenia: definitions and outcome parameters